Skip to content

Effect of Infliximab on treatment of cirrhosis.

Evaluation of the effects of anti-TN-alpha (Infliximab) on necrosis, inflammation, fibrosis and overall survival in patients with cryptogenic cirrhosis.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016052228003N1
Enrollment
30
Registered
2016-06-15
Start date
2016-07-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cryptogenic cirrhosis. Other and unspecified cirrhosis of liver

Interventions

Intervention 1: control group: traditional conservative treatments. Intervention 2: Intervention group: traditional conservative treatments + infliximab (loading dose: 3 mg/kg & maintenance dose: 3 mg
q 2 weeks).
Treatment - Other
Treatment - Drugs
control group: traditional conservative treatments
Intervention group: traditional conservative treatments + infliximab (loading dose: 3 mg/kg & maintenance dose: 3 mg/kg for 12 weeks
q 2 weeks)

Sponsors

Research center for infectious diseases of digestive system, research adjutancy of Ahvaz Jundishapur
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: existence of proved cryptogenic cirrhosis; lack of experience with infliximab treatment in cirrhosis due to it; having informed consent Exclusion criteria: Decompensated cirrhosis; active or latent tuberculosis; patient's trend to leaving the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement of MELD score. Timepoint: 0- 3th month- 6th month. Method of measurement: according to creatinine, billirubine, and INR- Range: 6-40.

Secondary

MeasureTime frame
Decrease of numbers of hospitalization and decrease of cirrhosis complications. Timepoint: 0- 3th month- 6th month. Method of measurement: Evaluation of patient's medical file and disease progression.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSanaz Taherpour

Ahvaz Jundishapur University of Medical Sciences

Taherpoursanaz@gmail.com+98 61 3292 1839

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026